Suppl. document 3

Patients withdrawing because of adverse events, serious and all neurological adverse events observed in patients included in double-blind clinical trials with eslicarbazepine

Drug dose: 800 mg/day

Outcome or Subgroup / Studies / Participants / Statistical Method / Effect Estimate
Patients withdrawing for AEs / 3 / 573 / Risk Difference (M-H, Random, 95% CI) / 0.07 [-0.01, 0.15]
I2 = 72%
Serious AE / 3 / 573 / Risk Difference (M-H, Fixed, 95% CI) / 0.02 [-0.01, 0.05]
I2 = 68%
Somnolence / 3 / 573 / Risk Difference (M-H, Fixed, 99% CI) / 0.04 [-0.03, 0.10]
I2 = 0%
Dizziness / 3 / 573 / Risk Difference (M-H, Fixed, 95% CI) / 0.14 [0.08, 0.19]
I2 = 13%
Vertigo / 2 / 372 / Risk Difference (M-H, Fixed, 95% CI) / 0.02 [-0.01, 0.04]
I2 = 0%
Coordination abnormal / 2 / 373 / Risk Difference (M-H, Random, 95% CI) / 0.04 [-0.04, 0.12]
I2 = 74%
Diplopia / 3 / 573 / Risk Difference (M-H, Random, 95% CI) / 0.06 [-0.03, 0.14]
I2 = 88%
Fatigue / 1 / 201 / Risk Difference (M-H, Fixed, 99% CI) / -0.00 [-0.08, 0.08]
I2 = na
Vomiting / 2 / 373 / Risk Difference (M-H, Random, 99% CI) / 0.05 [-0.06, 0.17]
I2 = 71%
Nausea / 2 / 373 / Risk Difference (M-H, Fixed, 99% CI) / 0.06 [0.00, 0.13]
I2 = 0%
Headache / 3 / 573 / Risk Difference (M-H, Fixed, 99% CI) / 0.02 [-0.05, 0.08]
I2 = 49%

Drug dose: 1200 mg/day

Outcome or Subgroup / Studies / Participants / Statistical Method / Effect Estimate
Patients withdrawing for AEs / 4 / 712 / Risk Difference (M-H, Random, 95% CI) / 0.11 [-0.00, 0.21]
I2 = 82%
Serious AE / 4 / 569 / Risk Difference (M-H, Fixed, 95% CI) / 0.02 [-0.01, 0.04]
I2 = 0%
Somnolence / 4 / 712 / Risk Difference (M-H, Fixed, 99% CI) / 0.05 [-0.01, 0.11]
I2 = 0%
Dizziness / 4 / 712 / Risk Difference (M-H, Random, 95% CI) / 0.17 [0.02, 0.32]
I2 = 93%
Vertigo / 2 / 371 / Risk Difference (M-H, Fixed, 95% CI) / 0.04 [0.01, 0.08]
I2 = 0%
Coordination abnormal / 2 / 365 / Risk Difference (M-H, Fixed, 95% CI) / 0.05 [0.00, 0.10]
I2 = 0%
Diplopia / 3 / 569 / Risk Difference (M-H, Fixed, 95% CI) / 0.07 [0.03, 0.10]
I2 = 57%
Fatigue / 1 / 198 / Risk Difference (M-H, Fixed, 99% CI) / 0.02 [-0.07, 0.11]
I2 = na
Vomiting / 3 / 508 / Risk Difference (M-H, Fixed, 99% CI) / 0.05 [0.00, 0.10]
I2 = =%
Nausea / 3 / 508 / Risk Difference (M-H, Fixed, 99% CI) / 0.08 [0.02, 0.14]
I2 = 52%
Headache / 3 / 569 / Risk Difference (M-H, Fixed, 99% CI) / 0.05 [-0.02, 0.12]
I2 = 34%


Patients withdrawing because of adverse events, serious and all neurological adverse events observed in patients included in double-blind clinical trials with lacosamide

Drug dose: 200 mg/day

Outcome or Subgroup / Studies / Participants / Statistical Method / Effect Estimate
Patients discontinuing because AEs / 2 / 530 / Risk Difference (M-H, Random, 95% CI) / 0.05 [-0.04, 0.14]
I2 = 73%
1.2 Serious AEs / 2 / 530 / Risk Difference (M-H, Fixed, 95% CI) / 0.04 [0.00, 0.08]
I2 = 0%
1.3 Dizziness / 2 / 530 / Risk Difference (M-H, Fixed, 95% CI) / 0.09 [0.04, 0.14]
I2 = 56%
1.4 Vertigo / 1 / 326 / Risk Difference (M-H, Fixed, 95% CI) / 0.05 [0.01, 0.09]
I2 = na
1.8 Diplopia / 2 / 530 / Risk Difference (M-H, Fixed, 95% CI) / 0.05 [0.02, 0.08]
I2 = 60%
1.10 Nystagmus / 1 / 204 / Risk Difference (M-H, Fixed, 99% CI) / -0.02 [-0.09, 0.05]
I2 = na
1.11 Somnolence / 1 / 204 / Risk Difference (M-H, Fixed, 99% CI) / 0.01  [-0.08, 0.10]
I2 = na
1.13 Headache / 2 / 530 / Risk Difference (M-H, Fixed, 99% CI) / 0.02  [-0.04, 0.10]
I2 = 0%
1.14 Fatigue / 2 / 530 / Risk Difference (M-H, Fixed, 99% CI) / 0.03  [-0.02, 0.08]
I2 = 0%
1.17 Nausea / 2 / 530 / Risk Difference (M-H, Fixed, 99% CI) / 0.04  [-0.02, 0.08]
I2 = 0%
1.18 Vomiting / 2 / 530 / Risk Difference (M-H, Fixed, 99% CI) / 0.05  [-0.01, 0.08]
I2 = 66%
1.25 Ataxia/coordination abn / 2 / 530 / Risk Difference (M-H, Fixed, 95% CI) / 0.03 [-0.00, 0.05]
I2 = 1%


Drug dose: 400 mg/day

Outcome or Subgroup / Studies / Participants / Statistical Method / Effect Estimate
Patients discontinuing because AEs / 3 / 835 / Risk Difference (M-H, Fixed, 95% CI) / 0.12 [0.08, 0.16]
I2 = 0%
Serious AEs / 3 / 835 / Risk Difference (M-H, Fixed, 95% CI) / 0.03 [0.00, 0.07]
I2 = 0%
Dizziness / 3 / 835 / Risk Difference (M-H, Random, 95% CI) / 0.19 [0.06, 0.32]
I2 = 86%
Vertigo / 1 / 322 / Risk Difference (M-H, Fixed, 95% CI) / 0.04 [0.00, 0.09]
I2 = na
Diplopia / 3 / 835 / Risk Difference (M-H, Random, 95% CI) / 0.08 [0.05, 0.12]
I2 = 0%
Nystagmus / 2 / 513 / Risk Difference (M-H, Fixed, 99% CI) / 0.02 [-0.04, 0.07]
I2 = 0%
Somnolence / 2 / 513 / Risk Difference (M-H, Fixed, 99% CI) / 0.06  [-0.02, 0.11]
I2 = 0%
Headache / 3 / 835 / Risk Difference (M-H, Fixed, 99% CI) / 0.05 [-0.01, 0.10]
I2 = 69%
Fatigue / 2 / 527 / Risk Difference (M-H, Fixed, 99% CI) / 0.04 [-0.01, 0.10]
I2 = 0%
Nausea / 3 / 835 / Risk Difference (M-H, Fixed, 99% CI) / 0.07  [0.02, 0.11]
I2 = 0%
Vomiting / 3 / 835 / Risk Difference (M-H, Fixed, 99% CI) / 0.06 [0.02, 0.10]
I2 = 0%
Tremor / 1 / 308 / Risk Difference (M-H, Fixed, 99% CI) / 0.02 [-0.07, 0.10]
I2 = na
Ataxia and coordination abn / 3 / 728 / Risk Difference (M-H, Fixed, 95% CI) / 0.08  [0.05, 0.11]
I2 = 0%


Patients withdrawing because of adverse events, serious and neurological adverse events observed in patients included in double-blind clinical trial with oxcarbazepine

Drug dose: 600 mg/day

Outcome or Subgroup / Studies / Participants / Statistical Method / Effect Estimate
Patients withdrawing because of AEs / 1 / 341 / Risk Difference (M-H, Fixed, 95% CI) / 0.03 [-0.03, 0.10]
I2 = na
Serious AEs / 1 / 341 / Risk Difference (M-H, Fixed, 95% CI) / 0.02 [-0.03, 0.07]
I2 = na
Dizziness / 1 / 341 / Risk Difference (M-H, Fixed, 95% CI) / 0.12 [0.04, 0.21]
I2 = na
Vertigo / 1 / 341 / Risk Difference (M-H, Fixed, 95% CI) / 0.04 [-0.00, 0.09]
I2 = na
Diplopia / 1 / 341 / Risk Difference (M-H, Fixed, 95% CI) / 0.09  [0.03, 0.15]
I2 = na
Nystagmus / 1 / 341 / Risk Difference (M-H, Fixed, 99% CI) / 0.03 [-0.04, 0.09]
I2 = na
Somnolence / 1 / 341 / Risk Difference (M-H, Fixed, 99% CI) / 0.08 [-0.02, 0.18]
I2 = na
Fatigue / 1 / 341 / Risk Difference (M-H, Fixed, 99% CI) / 0.08 [-0.01, 0.17]
I2 = na
Tremor / 1 / 341 / Risk Difference (M-H, Fixed, 99% CI) / -0.00 [-0.06, 0.05]
I2 = na
Vomiting / 1 / 341 / Risk Difference (M-H, Fixed, 99% CI) / 0.08 [0.01, 0.16]
I2 = na
Nausea / 1 / 341 / Risk Difference (M-H, Fixed, 99% CI) / 0.07 [-0.02, 0.16]
Headache / 1 / 341 / Risk Difference (M-H, Fixed, 99% CI) / 0.08 [-0.04, 0.21]
I2 = na
Ataxia/abn gait / 1 / 341 / Risk Difference (M-H, Fixed, 95% CI) / 0.10  [0.02, 0.15]
I2 = na


Drug dose 1200 mg/day

Outcome or Subgroup / Studies / Participants / Statistical Method / Effect Estimate
Patients withdrawing because of AEs / 1 / 350 / Risk Difference (M-H, Fixed, 95% CI) / 0.27 [0.19, 0.36]
I2 = na
Serious AEs / 1 / 350 / Risk Difference (M-H, Fixed, 95% CI) / -0.00 [-0.05, 0.05]
I2 = na
Dizziness / 1 / 350 / Risk Difference (M-H, Fixed, 95% CI) / 0.19 [0.10, 0.27]
I2 = na
Vertigo / 1 / 350 / Risk Difference (M-H, Fixed, 95% CI) / 0.09 [0.04, 0.14]
I2 = na
Diplopia / 1 / 350 / Risk Difference (M-H, Fixed, 95% CI) / 0.26 [0.18, 0.33]
I2 = na
Nystagmus / 1 / 350 / Risk Difference (M-H, Fixed, 99% CI) / 0.16 [0.08, 0.25]
I2 = na
Somnolence / 1 / 350 / Risk Difference (M-H, Fixed, 99% CI) / 0.16 [0.05, 0.26]
I2 = na
Fatigue / 1 / 350 / Risk Difference (M-H, Fixed, 99% CI) / 0.05 [-0.03, 0.13]
I2 = na
Tremor / 1 / 350 / Risk Difference (M-H, Fixed, 99% CI) / 0.04 [-0.03, 0.10]
I2 = na
Vomiting / 1 / 350 / Risk Difference (M-H, Fixed, 99% CI) / 0.20 [0.11, 0.30]
I2 = na
Nausea / 1 / 350 / Risk Difference (M-H, Fixed, 99% CI) / 0.16 [0.06, 0.26]
I2 = na
Headache / 1 / 350 / Risk Difference (M-H, Fixed, 99% CI) / 0.03 [-0.09, 0.15]
I2 = na
Ataxia/abn gait / 1 / 350 / Risk Difference (M-H, Fixed, 95% CI) / 0.21 [0.13, 0.28]
I2 = na